Erschienen in:
01.07.2006 | Original Article
A new MAGE-4 antigenic peptide recognized by cytolytic T lymphocytes on HLA–A24 carcinoma cells
verfasst von:
Sabrina Ottaviani, Didier Colau, Pierre van der Bruggen, Pierre van der Bruggen
Erschienen in:
Cancer Immunology, Immunotherapy
|
Ausgabe 7/2006
Einloggen, um Zugang zu erhalten
Abstract
“Cancer-germline” genes such as those of the MAGE family are expressed in many tumors and in male germline cells, but are silent in other normal tissues. They encode tumor specific antigens that are used in cancer immunotherapy trials. MAGE-4 antigens represent promising targets for cancer immunotherapy because gene MAGE-4 is expressed in more than 50% of carcinomas of the esophagus, lung, bladder, and head and neck. To identify new MAGE-4 antigenic peptides, we have folded HLA–A*2402 soluble molecules with candidate peptide NYKRCFPVI, which corresponds to amino acids 143 to151 of the MAGE-4 protein. A24/MAGE-4 multimers were used to isolate a cytolytic T cell clone that recognized the MAGE-4 peptide from the blood cells of a donor without cancer. This clone lysed specifically A24 carcinoma cells expressing MAGE-4. The antigenic peptide is processed more efficiently in tumor cells pre-treated with IFN-γ. This MAGE-4 peptide could represent an interesting target for immunotherapy because it is presented by HLA–A24 molecules, which are widely expressed in different ethnic groups.